Skip to main content
. 2017 Jun 8;12(6):e0179202. doi: 10.1371/journal.pone.0179202

Fig 5. Bevacizumab increases VEGFR1 and VEGFR2 expression.

Fig 5

(A, B) Telomerase inhibitors were combined to bevacizumab (100 μg/ml) and then VEGFR1 (A) and VEGFR2 (B) were quantified by real-time PCR. (C, D) Cells were transiently transfected with either control siRNA or hTERT siRNA and treated with bevacizumab (100 μg/ml). VEGFR1 (C) and VEGFR2 (D) were quantified by real-time qPCR. (E, F) HUVECs were cultured in the presence of telomerase inhibitors for 48 h and hTERT siRNA for 72 h. The expression of VEGFR1 (E) and VEGFR2 (F) were quantified by real-time PCR. Results were expressed as the mean ± SD from three experiments.